Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

7 Residual cancer cells present beyond these times are likely to be resistant to treatment. Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability ...

Outpatient administration of CAR T-cell therapies can reduce costs and improve patient satisfaction, with evolving ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

CDK4/6 inhibitor Verzenio (abemaciclib) was the third drug in the class to reach the market, first approved in 2017 as a second-line treatment for post-menopausal patients with hormone receptor ...

"Addition of metformin to letrozole and abemaciclib is feasible and safe, and appears to induce deeper responses, including complete responses not reported with any of the previous CDK4/6 ...